title: Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
abstract: The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Medical School, Deokjin-gu, Jeonju, Republic of Korea.
authors.forename: Ho-Young
authors.initials: HY
authors.lastname: Yhim
authors.forename: Na-Ri
authors.initials: NR
authors.lastname: Lee
authors.forename: Eun-Kee
authors.initials: EK
authors.lastname: Song
authors.forename: Chang-Yeol
authors.initials: CY
authors.lastname: Yim
authors.forename: So Yeon
authors.initials: SY
authors.lastname: Jeon
authors.forename: Seunghwan
authors.initials: S
authors.lastname: Shin
authors.forename: Jeong-A
authors.initials: JA
authors.lastname: Kim
authors.forename: Hee Sun
authors.initials: HS
authors.lastname: Kim
authors.forename: Eun Hae
authors.initials: EH
authors.lastname: Cho
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Kwak
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000032:analysis / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques; D020360:Neoadjuvant Therapy; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D028761:Withholding Treatment
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl